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REVIEW
Abstract: Prostate cancer is one of the most complex and enigmatic oncologic problems 
in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally 
protracted and variable clinical course and high association with treatment-related morbidity 
raise serious questions about the ideal treatment strategy for the individual patient. 5 alpha-
reductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. 
Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and 
treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized 
clinical trial to decrease the risk of prostate cancer with a reduction of almost 25%. Additionally, 
a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that ﬁ  nasteride 
improves the performance characteristics of prostate-speciﬁ  c antigen (PSA) blood test as a 
screening tool for prostate cancer, for both cancer detection as well as for detection of high risk 
disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for 
all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding 
the toxicity of medical and surgical castration.
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Introduction
Prostate cancer is the most common noncutaneous malignancy in males. The American 
Cancer Society estimates that in the year 2006, a total of 234 460 men will be diagnosed 
with prostate cancer and 27 350 will die of this disease (Jemal et al 2006). At the start 
of the year 2003, nearly 2 million American men were living with prostate cancer. 
Most commonly a disease of elderly men, the average age at diagnosis is 68 and 27.3% 
of all new diagnoses are in men 75 years of age or older (Ries et al 2006).
The characteristics of prostate cancer have changed dramatically since the 
introduction of prostate-specific antigen (PSA)-based screening in 1986. PSA 
screening has led to a drastic increase in the detection rate of prostate cancer 
along with an associated downward stage migration. While there are no 
prospective, randomized studies that prove earlier detection of prostate cancer 
leads to decreased mortality, the reality is that widespread PSA-based screening 
for prostate cancer has continued. Taking into consideration that many tumors 
currently detected may be of an indolent nature, a current challenge is identifying 
the patient who may benefit from treatment for whom side effects of treatment may 
be acceptable. 
The high prevalence and considerably lower mortality of prostate cancer, coupled 
with the signiﬁ  cant potential morbidity of therapy for prostate cancer, have sparked 
much interest in alternative approaches against prostate cancer such as prevention 
(Thompson et al 2003), minimally invasive surgical therapies (Ahmed et al 2005; 
Tooher et al 2006) and active surveillance strategies (Carter et al 2002). Well designed 
randomized clinical trials addressing questions in these areas will hopefully lead to 
more efﬁ  cacious and appropriate treatment of prostate cancer with lower disease 
speciﬁ  c mortality, while minimizing treatment related morbidity. Medical therapy 
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with 5 alpha-reductase (5AR) inhibitors may play a role in 
accomplishing some of these goals.
The results from the Prostate Cancer Prevention Trial 
(PCPT) have sparked interest in the various roles of 5AR 
inhibitors in the management of prostate cancer. In this 
review, we examine the pharmacology of 5AR inhibitors 
and how this class of agents relate to the pathophysiology 
of prostate cancer as well as their role in prevention and 
treatment of prostate cancer. 
Androgens and prostate cancer
The physiologic functions and pathologic conditions of 
the prostate, like all other endocrine glands, are regulated 
by numerous endogenous hormones and growth factors. 
Testosterone is the predominant circulating androgen in 
males. It is a steroid hormone, synthesized from cholesterol 
in Leydig cells within the interstitium of the testis. Its 
production is stimulated by luteinizing hormone (LH), 
secreted by the anterior pituitary gland in response to the 
cyclic release of luteinizing hormone releasing hormone 
(LHRH) by the hypothalamus. LHRH release, in a negative 
feedback fashion, is inhibited by testosterone. Greater than 
95% of endogenous androgen is produced by the testis, with 
the remainder produced as androstendione by the adrenal 
cortex. This small amount of nontesticular androgen has 
a minimal impact on prostate function in physiologically 
normal males (Partin and Rodriguez 2002).
Testosterone is taken up from the systemic circulation 
by the prostatic glandular and stromal cells. Once within the 
prostate, testosterone is rapidly and irreversibly converted 
to dihydrotestosterone (DHT) by the enzyme 5AR. This 
leads to a ﬁ  ve-fold higher concentration of DHT versus 
testosterone within the intracellular prostate, versus an 
eleven-fold higher concentration of testosterone within the 
circulation. DHT then binds to the androgen receptor within 
the cytosol, is actively transported into the nucleus, and 
serves as a transcription factor for prostatic gene expression 
and thus prostatic cellular function. The higher concentration 
of intracellular DHT, in addition to its higher afﬁ  nity for 
the androgen receptor, support the importance of 5AR in 
normal and pathologic prostate physiology (Partin and 
Rodriguez 2002).
In 1974, both Walsh and Imperato-McGinley described 
the deficiency of 5AR as an inheritable form of 
pseudohermaphroditism (Imperato-McGinley et al 1974; 
Walsh et al 1974). Affected individuals known locally as 
“guevedoces”, literally “penis at 12 years of age”, were 
originally discovered in a remote village in the Dominican 
Republic where this enzyme deficiency was highly 
prevalent. Clinical manifestations of this disorder include 
the presence of ambiguous genitalia, undescended testicles, 
a blind vaginal pouch, a small clitoris-like phallus and 
absence of all internal female reproductive structures. At 
puberty, the phenotype of these individuals changes to 
a more normal male pattern manifested by development 
of a functional penis, deepening of the voice, muscle 
development, etc. However, adult males with this condition 
have a diminutive prostate and lack male pattern baldness, 
facial hair, and acne (Imperato-McGinley et al 1974). 
Subsequent clinical evaluation of affected individuals with 
magnetic resonance imaging, trans-rectal ultrasound and 
prostate biopsy conﬁ  rmed presence of a small, atrophic 
prostate. PSA was undetectable and affected individuals 
developed neither benign prostatic hyperplasia (BPH) nor 
prostate cancer (Imperato-McGinley et al 1992).
Identiﬁ  cation of individuals with congenital deﬁ  ciency 
of 5AR has served as a naturally occurring model ultimately 
leading to the development of a pharmacologic inhibitor of 
5AR. Finasteride is an orally active, competitive inhibitor of 
the nicotinamide adenine dinucleotide phosphate, reduced 
form (NADPH)-dependent 5AR enzyme’s type 2 isozyme. 
Despite its steroid structure, it has no afﬁ  nity for any steroid 
receptors, including androgens, estrogens, and progesterone 
(Stoner 1992), allowing the inhibition of 5AR without 
concomitant binding at other physiologic locales. Guided by 
early animal models (Brooks et al 1981, 1982; Wenderoth 
et al 1983), several investigators described the ability of 
ﬁ  nasteride to suppress serum DHT to approximately 70% 
of baseline levels in male humans (Rittmaster et al 1989; 
Stoner 1990, 1992; Gormley et al 1992). Since that time, 
several large scale clinical trials have demonstrated the 
efﬁ  cacy of ﬁ  nasteride in the medical management of BPH 
(Rittmaster et al 1989; Gormley et al 1992; Stoner 1992; 
McConnell et al 1998, 2003) and in the prevention of 
prostate cancer (Thompson et al 2003).
In the 1990s, dutasteride was identiﬁ  ed as an inhibitor 
of both isozymes (type 1 and type 2) of 5AR. Nonselective 
inhibition of both 5AR isozymes produces more than a 
90% reduction in serum DHT (Bramson et al 1997). While 
type 2 5AR is the predominant isozyme within the prostate, 
its inhibition by ﬁ  nasteride may lead to up regulation of 
type 1 5AR at extraprostatic sites (ie, liver and skin) with 
resultant paracrine effects (elevated serum DHT) on the 
prostate (Bramson et al 1997). Additionally, dutasteride has 
a signiﬁ  cantly longer half life (~180 hours) than ﬁ  nasteride 
(5–8 hours) (Steiner 1996; Bramson et al 1997). The clinical Clinical Interventions in Aging 2006:1(4) 427
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signiﬁ  cance of the distinctions between ﬁ  nasteride and 
dutasteride on malignant prostate pathophysiology has been 
postulated (Andriole et al 2004), but has yet to be conﬁ  rmed 
in clinical trials.
In the absence of prostate cancer, 5AR inhibition has 
a dramatic effect on serum PSA. An approximate 50% 
reduction in the PSA from baseline is to be expected after 
6 months of continuous therapy with either ﬁ  nasteride or 
dutasteride (Gormley et al 1992; Roehrborn et al 2002). 
When patients on therapy with 5AR inhibitors for 6 months 
or greater undergo PSA based screening for prostate cancer, 
the measured PSA should be doubled before comparing it 
with reference values in consideration for prostate needle 
biopsy (Andriole et al 1998). After several years of therapy 
with 5AR inhibitors, the measured PSA must be increased 
by a factor of 2.5, to account for continued PSA decrease in 
treated men (Etzioni et al 2005).
Prevention of prostate cancer with 
5-alpha reductase inhibitors
Men with congenital deﬁ  ciency of 5AR have low levels of 
DHT, a diminutive prostate, and complete lack of prostatic 
glandular epithelium (Imperato-McGinley et al 1974, 1992) 
and are notable for a lack of reported cases of adenocarcinoma 
of the prostate. These ﬁ  ndings, along with the well known 
androgen sensitive nature of prostate cancer prompted two 
large scale clinical trials investigating the possible role of 
5AR inhibitors in the prevention of prostate cancer: the 
Prostate Cancer Prevention Trial (PCPT) and the Reduction 
by Dutasteride of Prostate Cancer Events (REDUCE) 
(Thompson et al 2003; Andriole et al 2004).
The PCPT was a multicenter, randomized, double blind, 
placebo-controlled clinical trial comparing ﬁ  nasteride with 
placebo in the prevention of adenocarcinoma of the prostate. 
18 882 men over the age of 55, with a PSA of 3.0 ng/ml 
or lower and a normal digital rectal examination (DRE) 
were randomized to receive 7 years of ﬁ  nasteride (5 mg) 
or placebo daily. The study participants were monitored 
with annual PSA (blindly adjusted in the finasteride 
group) and DRE. Transrectal ultrasound guided biopsies 
were performed for PSA greater than or equal to 4 ng/ml 
or for an abnormal DRE. Additionally, all men were 
recommended to undergo an end of study biopsy after the 
7 years of treatment had elapsed (Thompson et al 2003). 
Of the 9060 men included in the ﬁ  nal statistical analysis, 
18.4% of men in the ﬁ  nasteride group were diagnosed with 
adenocarcinoma of the prostate, compared with 24.4% in the 
placebo group; a 24.8% relative risk reduction (p<0.001). 
A signiﬁ  cant difference persisted across all subgroups 
analyzed and approximately 98% of cancers in both groups 
were organ conﬁ  ned. 
Despite the impressive 24.8% relative risk reduction 
in the diagnosis of prostate cancer in the PCPT study 
population, several issues have prevented the widespread 
acceptance of ﬁ  nasteride as preventative therapy for prostate 
cancer. First and foremost, ﬁ  nasteride therapy was associated 
with an increased diagnosis rate of poorly differentiated 
prostate cancer compared with placebo (37.0% vs 22.2% 
of cancers diagnosed; 6.4% vs 5.1% overall) (Thompson et 
al 2003). Additionally, prostate cancer diagnosis rates were 
far higher than expected in both study groups (18.4% and 
24.8% in this relatively low-risk group followed for 7 years 
vs lifetime prevalence of approximately 17%). Finally, 
nearly half of all positive cancer diagnoses were from end-
of-study biopsies, tumors whose clinical signiﬁ  cance is 
unknown (Grover et al 2006).
The PCPT was met with immediate skepticism by 
some investigators and clinicians, fueled by concerns that 
ﬁ  nasteride had selected for and accelerated the growth of 
high grade tumors (Scardino 2003). Subsequent analysis of 
PCPT data provide an alternative hypothesis to explain the 
slightly higher percentage of high grade tumors detected 
in the treatment group (Etzioni et al 2005; Thompson et al 
2005, 2006). First, the greatest difference in the proportion 
of high versus low-grade cancers detected between the 
treatment and placebo groups was seen in those study 
subjects undergoing for-cause biopsies as opposed to end-
of-study biopsies. The increased hazard ratio for detecting 
high grade prostate cancer in the treatment group did not 
increase over the course of the clinical trial. In fact, the 
number of men diagnosed with high grade prostate cancer 
during the end-of-study biopsies were similar across both 
study groups. A subsequent analysis found that ﬁ  nasteride 
inﬂ  uenced the characteristics of PSA as a screening test, 
increasing its sensitivity for all grades of prostate cancer 
in general, and high grade prostate cancer in particular 
(Thompson et al 2006). Additionally, PSA is more sensitive 
for high grade prostate cancer at various PSA cutoff levels 
ranging from 1.1 ng/ml to 10.1 ng/ml (Thompson et al 
2005), decreasing the false negative rate and increasing 
the rate of diagnosis of high grade tumors. Therefore, the 
combination of cancer chemoprevention, PSA reduction (in 
benign disease), and increased sensitivity of PSA for high 
grade prostate cancer may have led to the increased rate of 
diagnosis of high grade prostate cancer in the ﬁ  nasteride 
group despite an overall reduction in the incidence of Clinical Interventions in Aging 2006:1(4) 428
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prostate cancer diagnosis. Other analyses from the PCPT 
regarding the effect of ﬁ  nasteride on tumor grade and the 
interaction of the reduction in gland volume with detection 
of cancer and high grade cancer are expected in the near 
future.
Expression of type 1 5AR is greater in some cell lines 
of neoplastic prostate tissue (Iehle et al 1999; Andriole 
et al 2004). As discussed previously, dutasteride inhibits 
both type-1 and type-2 5AR. Secondary analysis of a large 
scale clinical trial evaluating the efﬁ  cacy of dutasteride 
for BPH noted a 1.1% rate of prostate cancer diagnosis in 
the treatment group compared with 1.9% in the placebo 
group (Roehrborn et al 2002). A clinical trial is underway 
to prospectively evaluate the role of dutasteride in the 
prevention of prostate cancer. The REDUCE trial is a 
multicenter, randomized, international, placebo-controlled, 
double blind clinical trial initiated in 2003 which is designed 
to evaluate the ability of dutasteride to decrease the risk of 
biopsy detectable prostate cancer in men with moderately 
elevated PSA levels (Andriole et al 2004).The relative 
efﬁ  cacy of ﬁ  nasteride versus dutasteride for prevention 
must await the conclusion of this trial but the substantially 
different characteristics of subjects in the two studies will 
probably make such conclusions challenging regardless of 
the study’s outcomes.
Treatment of prostate cancer with 
5-alpha reductase inhibitors
The heterogeneous behavior of prostate cancer as well as 
multiple factors limiting patient accrual are some of the 
inherent challenges in the development and completion 
of clinical trials comparing various therapeutic modalities 
(active surveillance, surgical extirpation, surgical ablation, 
radiation therapy, hormonal therapy, and chemotherapy). 
As a result, studies are typically small, poorly controlled, 
and fraught with a number of biases (Cookson 2006). 
However, the search for the optimal method of prostate 
cancer management (greatest cancer control rate with lowest 
risk of complications and side effects) continues. In spite 
of these limitations, a number of studies have addressed 
the potential role of 5AR inhibitors in the management of 
prostate cancer. 
Murine prostatic carcinoma has been used for the 
investigation of various hormonal therapy regimens. Various 
cell lines of murine prostate cancer (Dunning R3327, 
Fisher 344) share several important characteristics with 
human prostate cancer, including basic histology, slow rate 
of growth, hormonal sensitivity, and expression of 5AR 
(Zaccheo et al 1997). Murine models have demonstrated 
the ability of various 5AR inhibitors to inhibit macroscopic 
rat prostate carcinogenesis (Tsukamoto et al 1998) and 
decrease the rate of rat prostate cancer growth (Zaccheo 
et al 1997, 1998). However, when compared with medical 
and surgical castration, 5AR inhibitors produce a lesser 
reduction in rat prostate cancer growth. In summary, results 
from animal model studies do not support the use of 5AR 
inhibitors as monotherapy for the treatment of prostate 
cancer.
While surgical extirpation or radiation therapy are 
commonly recommended for the treatment of localized 
prostate cancer, hormonal therapy is most frequently used 
for locally advanced disease, biochemical recurrence after 
localized therapy, and metastatic disease. Medical or surgical 
castration is the most effective form of hormonal therapy. 
However, it is poorly tolerated, with a high percentage of 
patients experiencing erectile dysfunction, loss of libido, 
“hot ﬂ  ashes”, osteoporosis, fatigue, and muscle wasting. 
While monotherapy with 5AR inhibitors has a minimal 
impact on prostate cancer (Presti et al 1992), there is much 
interest with combining the well tolerated hormonal effects 
of 5AR inhibitors with other therapeutic modalities.
To demonstrate the effect of 5AR inhibitors prior 
to localized therapy, Andriole and colleagues (2004) 
randomized 46 men with clinically localized prostate cancer 
to either dutasteride or placebo for 6 to 10 weeks prior to 
radical prostatectomy (Andriole et al 2004). While this 
double blind, prospective, randomized clinical trial was not 
powered for speciﬁ  c clinical end points, important effects 
of 5AR inhibition were observed. Serum and intraprostatic 
DHT was decreased by over 95% in the dutasteride group, 
versus no change in the placebo group. Cellular apoptosis 
indices were increased in the dutasteride group while 
measurements of vascular density were decreased. Finally, 
tumor volume and prostatic intraepithelial neoplasia (PIN) 
volume were lower in the dutasteride group. There were no 
clinical differences between the two groups (ie, pathologic 
grade/stage or rate of positive surgical margins) (Andriole 
et al 2004). The clinical signiﬁ  cance of the observed effects 
of dutasteride is unknown.
The morbidity associated with medical and surgical 
castration make them less attractive regimens for routine 
use in the prevention of recurrent disease or disease 
progression following localized therapy for prostate 
cancer (radical prostatectomy or radiation). Given its 
excellent tolerability, investigators have evaluated the role 
of ﬁ  nasteride as a potential agent for the prevention of Clinical Interventions in Aging 2006:1(4) 429
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disease progression. In a randomized, multicenter, placebo 
controlled clinical trial, Andriole and colleagues (1995) 
randomized 120 men to either placebo or 10 mg ﬁ  nasteride 
following radical prostatectomy with residual PSA levels. 
Finasteride did not prevent biochemical recurrence, but 
it delayed the onset of PSA progression by 6 months and 
the rate of PSA progression by 14 months after 2 years of 
therapy. This study, however, did not demonstrate a survival 
beneﬁ  t for the ﬁ  nasteride group compared with placebo.
Nonsteroidal antiandrogens (ﬂ  utamide, biclutamide, 
nilutamide) are competitive inhibitors for the androgen 
receptor. They do not suppress serum testosterone and 
thus, do not produce the side effects associated with 
castration (erectile dysfunction, loss of libido, “hot ﬂ  ashes”, 
osteoporosis, fatigue, and muscle wasting). While adjuvant 
monotherapy with nonsteroidal antiandrogens after radiation 
therapy or radical prostatectomy is not indicated for 
localized prostate cancer (McLeod et al 2006), high dose 
bicalutamide (150 mg daily) may play a role in the adjuvant 
management of locally advanced (Iversen et al 2000) or 
metastatic prostate cancer (Tyrrell et al 1998).
Combination therapy with nonsteroidal antiandrogens 
and 5AR inhibitors may provide better cancer control than 
antiandrogens alone, while continuing to avoid the toxicity 
of castration. In addition to decreasing intraprostatic DHT, 
5AR inhibitors down-regulate androgen receptor expression 
and may decrease the rate of androgen receptor mutation 
and subsequent androgen-independent prostate cancer 
(Wang et al 2004). Combination therapy with bicalutamide 
and ﬁ  nasteride inhibit the in vitro proliferation of prostate 
cancer cells; although to a lesser degree than castration. 
The combination of finasteride and flutamide has been 
shown to decrease the total prostatic weight in an equivalent 
manner to medical castration in a rat model (Fleshner and 
Trachtenberg 1992).
Several phase II trials have examined the effect of 
antiandrogens and ﬁ  nasteride as combination therapy for 
various stages of prostate cancer. Barqawi and colleagues 
(2003) noted a 58% rate of PSA regression to undetectable 
levels in 71 men with PSA recurrence after surgery or 
radiation therapy. Potency was maintained in all those 
evaluated. Combination therapy has also been used in 
advanced prostate cancer. Brufsky and colleagues (1997) 
treated 20 such men with ﬂ  utamide until PSA levels reached 
nadir (mean 9.1 weeks). The addition of ﬁ  nasteride further 
reduced PSA levels in 19 men. PSA levels continued to decline 
in 18 patients, declined to less than 1 ng/ml in 13 patients, 
and reached undetectable levels in 7 patients. Only 3 patients 
reported libido as “poor” and of the 11 patients potent at 
baseline, 8 were at least partially potent at last follow-up. 
Follow-up data demonstrates good durability of the PSA 
reduction, with a median time to failure of 30 months. At 
7 years, 25% of the original group had remained castration-
free. Five year overall survival was 65% (Oh et al 2003). 
A similar phase II trial with biclutamide and ﬁ  nasteride 
produced comparable results. Thirty of 36 patients with 
advanced prostate cancer reached a second PSA nadir after 
the addition of ﬁ  nasteride to biclutamide. Eleven were free 
of progression at last follow-up (mean 3.9 years). Of the 19 
who progressed, 12 reached a third PSA nadir after transition 
to standard medical androgen deprivation. The average 
time to failure of the treatment protocol was 21.3 months. 
All potent patients at baseline remained potent at second 
PSA nadir (Tay et al 2004).
The above studies have similar time to failure 
rates compared with castration (Potosky et al 2001). 
Unfortunately, the above studies are limited by their 
observational nature and small number of patients. While 
the combination of nonsteroidal antiandrogens and 5AR 
inhibitors seems like a viable option to avoid the toxicity 
of castration, long term, blinded, randomized, large scale 
clinical trials with survival data are necessary before 
deﬁ  nitive conclusions can be made.
Intermittent androgen deprivation allows for transient 
recovery of testosterone levels and may improve quality of 
life compared with permanent castration (Spry et al 2006). 
In a retrospective review of 101 individuals undergoing 
intermittent androgen deprivation, the “time off period” 
(when androgen deprivation was ceased) was prolonged 
from 15 to 31 months in individuals taking ﬁ  nasteride 5 mg 
daily (Scholz et al 2006). Improved quality of life was 
inferred, but not objectively quantiﬁ  ed. Additionally, there 
was no difference in disease speciﬁ  c survival (Scholz et al 
2006). At the time of writing there have been no randomized 
clinical trials validating the treatment of prostate cancer 
with intermittent androgen deprivation therapy and 5AR 
inhibitors.
Safety and tolerability of 5-alpha 
reductase inhibitors
There are extensive data from randomized clinical trials 
demonstrating the tolerability and safety of finasteride 
(McConnell et al 1998, 2003; Thompson et al 2003). The 
PLESS (Proscar Long-Term Efficacy and Safety) trial 
randomized 3040 men with BPH to 4 years of daily therapy 
with either ﬁ  nasteride (5 mg) or placebo. Symptoms and Clinical Interventions in Aging 2006:1(4) 430
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side effects were assessed every 4 months throughout the 
duration of the study. The drop out rate was higher with 
placebo (42%, p<0.001) versus ﬁ  nasteride (34%). Men 
in the placebo group were more likely to drop out due to 
lack of improvement or worsening of disease or to receive 
medical or surgical therapy for BPH. Statistically signiﬁ  cant 
drug-related adverse effects in the ﬁ  nasteride group included 
sexual dysfunction, breast enlargement/tenderness, and rash. 
However, the risk of these adverse effects was relatively 
low compared with placebo. Rates of decreased libido and 
impotence were different only during the ﬁ  rst year. There 
was no difference in the rates of serious adverse events 
(McConnell et al 1998).
During seven years of finasteride therapy versus 
placebo in the 18 882 men enrolled in the PCPT, similar 
tolerability rates were seen. In the placebo group, 28.9% of 
men temporarily discontinued therapy sometime during the 
7 year study, compared with 36.8% in the ﬁ  nasteride group 
(p<0.001). Reduced ejaculate volume, erectile dysfunction, 
loss of libido, and gynecomastia were more common in the 
ﬁ  nasteride group (p<0.001 for each comparison) but the 
overall risk for these adverse effects remained low compared 
with placebo. There was one case of breast cancer in each 
arm of the trial. The death rate (all-cause and prostate cancer) 
was not signiﬁ  cantly different between the two groups 
(Thompson et al 2003).
Despite the dual isotype blockade of 5AR and 
subsequent lower serum and prostatic levels of DHT, the 
tolerability of dutasteride is similar to that of ﬁ  nasteride. 
A 2 year study of dutasteride for the treatment of BPH 
revealed rates of impotence, decreased libido, ejaculation 
disorder, and gynecomastia similar to that of ﬁ  nasteride. 
The drug-related side-effects were transient with no 
statistically significant difference noted at 2 years. 
(Roehrborn et al 2002).
Summary and conclusions:
5AR inhibitors are effective for the medical management 
of BPH and their impact on the hormonal physiology of the 
prostate with relatively-low toxicity has led to studies of their 
use for the prevention and treatment of adenocarcinoma of 
the prostate. In spite of the fact that ﬁ  nasteride is the only 
agent shown to prevent prostate cancer in a randomized 
clinical trial, there is not widespread acceptance of its use 
for the prevention of this malignancy. More recent analyses 
of the improved performance of PSA for prostate cancer 
detection with ﬁ  nasteride as well as follow-up analyses 
may help resolve the issue of increased tumor grade with 
finasteride. The role of dutasteride in the prevention 
of prostate cancer remains to be proven. Finally, while 
preliminary data indicate a possible role of 5AR inhibitors 
in various forms of multimodal therapy for prostate cancer, 
there have been no deﬁ  nitive studies demonstrating improved 
survival with its use in any regimen. The role of 5AR 
inhibitors in the management of prostate cancer therefore 
remains unknown. 
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